Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Longeveron Inc (NQ: LGVN ) 3.900 +0.380 (+10.80%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Longeveron Inc < Previous 1 2 3 4 Next > BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Announces Plans to Release Year-End 2023 Financial Results, Corporate Update February 22, 2024 Via Investor Brand Network BioMedNewsBreaks — Longeveron Inc.’s (NASDAQ: LGVN) ELPIS Trial Demonstrates Potential Survival Benefit of Lomecel-B(TM) for HLHS Patients February 21, 2024 Via Investor Brand Network Study Links Ramadan Fasting to Lower Risk of Chronic Disease Development February 14, 2024 Via Investor Brand Network Longeveron Inc.’s (NASDAQ: LGVN) Long-Term Follow-Up Data from Its ELPIS I Clinical Trial Presented at the 2023 Annual Scientific Sessions of the American Heart Association February 07, 2024 Via Investor Brand Network Five Significant Strides Made in Alzheimer’s Research in 2023 January 05, 2024 Via Investor Brand Network BioMedNewsBreaks – H.C. Wainwright & Co. Reiterates ‘Buy’ Rating, $6 PT on Longeveron (NASDAQ: LGVN) February 06, 2024 Via Investor Brand Network Topics Intellectual Property Exposures COVID-19 Intellectual Property Dietician Tips for Boosting Muscle Mass, Living Longer January 31, 2024 Via Investor Brand Network BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Granted US Patent Allowance for Key Technology Behind Lead Investigation Product January 29, 2024 Via Investor Brand Network Topics Intellectual Property Exposures COVID-19 Intellectual Property Scientists Discover Alzheimer’s Can Be Categorized into Five Subtypes January 18, 2024 Via Investor Brand Network Studies Suggest Fasting Could Tone Down Alzheimer’s Signs December 22, 2023 Via Investor Brand Network BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Enters Definitive Agreement for $2.36M Registered Direct Offering December 21, 2023 Via Investor Brand Network BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Reports Additional Positive Clinical Data, Imaging Biomarker Results in Phase 2a Lomecel-B(TM) Trial December 20, 2023 Via Investor Brand Network Smart Trackers Could Detect Aging-Related Complications in Seniors December 12, 2023 Via Investor Brand Network BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Eyes ‘Encouraging’ Results from CLEAR MIND Trial December 01, 2023 Via Investor Brand Network Hidden Belly Fat Could Be a Precursor of Alzheimer’s Onset Years Later November 30, 2023 Via Investor Brand Network Longeveron Inc. (NASDAQ: LGVN) Encouraged by Positive Results from Phase 2a Trial in Patients with Mild AD; Explores Paths Forward for the Development of Lomecel-B(TM) November 21, 2023 Via Investor Brand Network Study Links Cat Parasite to Accelerated Frailty in Aging People November 16, 2023 Via Investor Brand Network BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Featured in Bell2Bell Podcast November 14, 2023 Via Investor Brand Network BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Study Survival Data Reported at AHA’s 2023 Scientific Sessions November 13, 2023 Via Investor Brand Network BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces 2023 Results, Provides Corporate Update November 10, 2023 Via Investor Brand Network Sex Hormones Could Influence Alzheimer’s Development, Researchers Say November 06, 2023 Via Investor Brand Network BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces Plans to Release Q3 2023 Financial Report, Host Corporate Update Call November 03, 2023 Via Investor Brand Network Longeveron Inc. (NASDAQ: LGVN) Validates Safety and Therapeutic Potential of its Lomecel-B(TM) Lead Investigational Product in its CLEAR MIND Phase 2a Clinical Trial October 30, 2023 Via Investor Brand Network BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Top-Line Results from Phase 2a Trial Spotlighted in Latest NNA Release October 24, 2023 Via Investor Brand Network BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Closes on $4M Registered Direct Offering October 16, 2023 Via Investor Brand Network BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Enters into $4M Registered Direct Offering October 12, 2023 Via Investor Brand Network BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Reports Top-Line Results for Phase 2a Lomecel-B Clinical Trial October 05, 2023 Via Investor Brand Network Longeveron Inc. (NASDAQ: LGVN) Eyeing Global HLHS, in addition to Alzheimer’s Disease, and Aging-Related Frailty Treatment Markets with Lomecel-B(TM), its Lead Investigational Product September 27, 2023 Via Investor Brand Network Longeveron Inc. (NASDAQ: LGVN) to Discuss Its Cellular Therapy Programs, Clinical Trial Progress at the 25th Annual H.C. Wainwright Global Investment Conference September 14, 2023 Via Investor Brand Network Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market September 12, 2023 By David Willey, Benzinga Via TheNewswire.com < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.